Details of the Drug

General Information of Drug (ID: DMTSVJM)

Drug Name
CJM112
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Phase 2 [1]
Chronic plaque psoriasis EA90.0 Phase 1/2 [2]
Multiple myeloma 2A83 Phase 1 [3]
Plaque psoriasis EA90.0 Phase 1 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Cross-matching ID
TTD ID
D0T5TN
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02998671) Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)